Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability and Pharmacokinetics of HBM9378 in Healthy Chinese Subjects
NCT05790694Phase 1Completed
- Sponsor
- Harbour BioMed
- Start
- Sep 2022
- Primary completion
- Oct 2023
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in asthma comparing HBM9378 (SKB378) Injection with Placebo (2 arms). Primary endpoints: Adverse Events at 160 days, Area Under the Curve from Time Zero to Last Quantifiable Concentration at 160 days and 5 more. Started Sep 2022; status: completed.
02
Drugs
WIN378
03
Conditions
asthma
Beyond the preview
Go deeper on NCT05790694.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05790694.